ArticleFrontiers in public health2024
Assessing and projecting the global impacts of Alzheimer's disease.
Article in Frontiers in public health, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Uncovering Necroptosis in Alzheimer's Disease: A Systematic Review of Evidence Across Experimental Models.Cellular and molecular neurobiology · 2025Pooled it
- The burden of brain disorders in Norway: an analysis of data from the global burden of disease study 2023.The Lancet regional health. Europe · 2026Article
- Entropy-Based Analysis of Olfactory EEG as a Candidate Biomarker for Early Mild Cognitive Impairment Detection: A Proof-of-Concept Study.Biosensors · 2026Article
- Article
- Association between MRI indicators of the glymphatic system and cognition in high-risk populations for Alzheimer's disease.The journal of prevention of Alzheimer's disease · 2026Article
- Genetic Burden andJournal of personalized medicine · 2026Article
- Article
- Effects of Dexmedetomidine on the Behavioral Outcomes in Streptozotocin-Induced Alzheimer's Disease Rats.Brain and behavior · 2026Article
- Metaheuristic-driven dual-layer model for classifying Alzheimer's disease stages.Frontiers in computational neuroscience · 2026Article
- Calibrating microglia states in Alzheimer's disease: decoding immune-metabolic networks and nano-targeted multicomponent therapies.Frontiers in immunology · 2026Review
- Sex-related upregulation of bone morphogenetic protein signaling inhibits adult neurogenesis in APPBiology of sex differences · 2025Article
- The long-term neuroprotective effect of MIND and Mediterranean diet on patients with Alzheimer's disease.Scientific reports · 2025Article
- The Transition to Caregiver in Advanced Alzheimer's Disease: From Emotional Connection to Care Responsibility-A Grounded Theory Approach.Nursing reports (Pavia, Italy) · 2025Article
- Analysis of the association between dietary sodium intake and cognitive function: a NHANES-based machine learning study and animal experimental validation.Frontiers in nutrition · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: This study aims to assess the global burden of Alzheimer's disease (AD) from 1990 to 2030, with a focus on incidence, mortality, and disability-adjusted life years (DALY). Methods: Data on the incidence rates, DALY rates, and death rates of AD across various geographic populations from 1990 to 2021 were obtained from the Global Burden of Disease (GBD) 2021 study. Generalized Additive Models (GAMs) were employed to forecast the disease burden from 2022 to 2030. Results: The projected global burden of Alzheimer's disease from 2022 to 2030 indicates a decrease in DALYs, with an Estimated Annual Percentage Change (EAPC) of -1.44 (95% CI: -1.45, -1.42). Similarly, death rates and incidence rates also show a decline, with EAPCs of -1.80 (95% CI: -1.83, -1.77) and -1.27 (95% CI: -1.29, -1.26) respectively. Gender-specific analysis reveals that the projected global incidence EAPC from 2022 to 2030 is estimated at -1.73 (95% CI: -1.75, -1.70) for males and -1.03 (95% CI: -1.04, -1.02) for females. Regionally, Andean Latin America and the Caribbean exhibit the highest positive EAPCs for DALYs at 0.94 (95% CI: 0.93, 0.94) and 0.59 (95% CI: 0.59, 0.60) respectively, while Eastern Europe shows the lowest EAPC at -16.31 (95% CI: -18.60, -13.95). Country-specific projections highlight Cyprus and Serbia with the highest positive EAPCs for DALYs at 12.55 (95% CI: 11.21, 13.91) and 9.6416 (95% CI: 8.86, 10.4333) respectively. On the other hand, Bahrain and Armenia exhibit significant negative EAPCs at -87.28 (95% CI: -94.66, -69.70) and -85.41 (95% CI: -92.80, -70.41). An analysis based on the Socio-Demographic Index (SDI) reveals that regions with higher SDI values have greater burdens of AD, with countries having SDI ≥ 0.8 showing significantly higher age-standardized Incidence Rates (ASIR), age-standardized Death Rates (ASDR), and age-standardized DALY rates compared to those with SDI < 0.8. Conclusion: From 1990 to 2030, global burden of AD is projected to decrease, with significant gender and regional disparities. Regions with higher SDI show higher disease burdens, underscoring the necessity for targeted interventions and customized public health strategies to effectively address AD in varied socio-economic settings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.